PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
about
Trial watch - inhibiting PARP enzymes for anticancer therapyNuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancerPARP expression in germ cell tumoursPhase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.Targeting tumor suppressor networks for cancer therapeutics.Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitroRepair of endogenous DNA base lesions modulate lifespan in miceMolecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancerTriple negative breast cancers have a reduced expression of DNA repair genesBiological and clinical significance of PARP1 protein expression in breast cancer.DNA damage response markers are differentially expressed in BRCA-mutated breast cancersPARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.Head and neck cancer: effective prevention in youth and predictive diagnostics for personalised treatment strategies according to biological differences.PARP1 Inhibitors: antitumor drug design.A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancerImmunoprofile from tissue microarrays to stratify familial breast cancer patientsPoly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.The role of PARP1 in the DNA damage response and its application in tumor therapy.Resistance to PARP-Inhibitors in Cancer Therapy.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.Somatic alterations as the basis for resistance to targeted therapies.Shotgun proteomics of archival triple-negative breast cancer samples.Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.PARP-1 Expression Quantified by [18F]FluorThanatrace: A Biomarker of Response to PARP Inhibition Adjuvant to Radiation Therapy.Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.Nuclear PARP1 expression and its prognostic significance in breast cancer patients.Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics.PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity.Hypoxia-induced protein CAIX is associated with somatic loss of BRCA1 protein and pathway activity in triple negative breast cancer.RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin β1/ Src signaling in triple negative breast cancer cells.
P2860
Q26745673-C7B0ACA6-164F-492D-B169-774CBAED5362Q28247712-B964FE71-7839-4B3D-B316-42D30914483CQ28287131-C3D48475-55DC-4D62-9FD2-EB305264741CQ33440778-D8535974-D1FE-4A59-BC9C-286889C1DC4AQ33657519-8FE90B1F-9917-42D3-A019-4D828B5CF07AQ33685138-44D13152-A054-45EE-B94D-2665A1C24B8FQ33828196-5A172414-DA8D-4D2A-86A3-F46CDCCFA3C7Q34016965-AF1B8F0D-ED6E-4C82-9B0D-8DD9FD84D4FDQ34306334-792852D6-4114-4187-B4D4-6F7393D7167DQ34493362-E0CBA27D-1157-410C-B116-8EFD9429BB61Q34794035-6596AB9F-43A5-46AE-B1D0-BC87E7305808Q35020363-4D3B7A75-19AF-4C1B-B420-322067DDFA45Q35131267-06161219-5448-41D2-BC37-5C9004CBD900Q35410911-27F655C9-1054-48A1-856D-F473B06E405BQ35684568-B040C175-5A53-45CC-82DF-4EB92E61BE32Q35919277-FB836E15-6560-4605-AE8F-3B6DF6868D37Q36117934-3ED05033-2DAD-4358-B00E-E3D8BF595F5FQ36175159-558A8D97-5E3B-4EE6-9382-26C6DC478313Q36186347-AECCBFEE-4F14-4813-8A51-A2ACCCAC5DD4Q36413928-B4CC0C57-53E9-467A-AE07-FBB7719DD111Q37996432-F60AF447-F527-4AAB-A085-052F0CA576A5Q38015737-713EBED8-E0B3-4EBC-94F0-9456E3F0A292Q38085600-5538F780-4F0D-459E-B749-26B8711933E9Q38087850-71ED7F2B-2F10-477A-A72C-F168985DCAD7Q38151570-8693980D-0227-4AEF-A6BD-D1100BF316B4Q38398043-B800B509-1FAF-4EDA-A051-9E066A5ED12AQ38683171-AEB10C49-ABDF-4E91-BC75-35E5F12617F6Q38707021-18BD204D-F153-4655-A095-4B946A93C00DQ38719698-459A5557-F992-4697-A10F-C5B1F0E8E89CQ38735426-E32622AE-95E6-4CCF-AB48-30712B263D0CQ41091405-253D5AB0-ED03-4A66-B38E-78DDACD1E1F6Q42055866-197766BB-5AD8-44D1-85E8-60CF3743B53DQ42107975-0D337983-E0E6-4D49-B65F-33D28755DEB6Q42371576-C4C86040-6E26-4D69-A663-398AC7BAC873Q42490495-E64C4260-6940-45C3-8B91-698D38622E7DQ43042008-78BF72BE-6D38-4809-9D22-1AEEB7D06F16Q45018412-9F2A672D-0722-4A17-AC81-6B632AAB5A7EQ45213264-A05AB253-C1CA-4783-9333-72255D2CEE43Q47156447-83F1C5B2-5B93-414F-9333-CC41DC168D8EQ47243874-5A99C19E-C25A-4811-A387-57940B897A5D
P2860
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@en
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@nl
type
label
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@en
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@nl
prefLabel
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@en
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@nl
P2093
P2860
P1476
PARP-1 expression in breast ca ...... for PARP-1 inhibitor therapy.
@en
P2093
Karol Gugala
Pawel Domagala
Tomasz Huzarski
Wenancjusz Domagala
P2860
P2888
P304
P356
10.1007/S10549-011-1441-2
P407
P50
P577
2011-03-17T00:00:00Z